Physician profile
Daniel Bender
NPI 1265736664
$10,048.74
in general payments reported to CMS, 2019-2025
29 companies · $2,545 in 2025
The $2,545 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,461 · 2022: $1,674 · 2023: $1,932 · 2024: $2,437 · 2025: $2,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,801 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,801.01 |
| Education | $113.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,092.41 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,487.67 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,203.99 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,064.89 | 2021-2025 | Tremfya, Stelara, Simponi |
| Ardelyx, INC. | $713.57 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $296.58 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $245.01 | 2023-2025 | Iqirvo, Bylvay |
| Celgene Corporation | $243.87 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $218.10 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $158.01 | 2021-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $128.47 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $127.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $121.55 | 2021-2024 | Suflave |
| Genzyme Corporation | $119.22 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $110.83 | 2021-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $101.43 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $97.81 | 2022-2024 | Dificid, Zinplava |
| Novo Nordisk INC | $80.70 | 2021 | |
| Ferring Pharmaceuticals INC. | $66.97 | 2021-2025 | Rebyota |
| Pfizer INC. | $58.37 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $53.12 | 2024 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $48.69 | 2025 | Voquezna |
| Redhill Biopharma INC. | $40.00 | 2021 | |
| Ironwood Pharmaceuticals, INC | $39.76 | 2022-2023 | Linzess |
| Celltrion USA INC. | $39.06 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $34.40 | 2022 | |
| Axonics, INC. | $32.24 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.08 | 2022 | |
| Boston Scientific Corporation | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.